Decoy Therapeutics Inc.
DCOY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001615219
No open-market purchases or sales by Decoy Therapeutics Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $31.0K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Decoy Therapeutics Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −13 vs. Q3 2022
- Shares held
- 73.3K
- −3.38M (−97.9%) vs. Q3 2022
- Total value
- $110.9K
- −$560.1K (−83.5%) vs. Q3 2022
- New holders
- 0
- 0 more added
- Sold out
- 13
- 9 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DCOY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 4 | $31.0K |
| Q1 2026 | 4 | $10.5K |
| Q4 2025 | 9 | $51.4K |
| Q3 2025 | 5 | $1.98K |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 13 | $101.9K |
| Q4 2023 | 16 | $169.8K |
| Q3 2023 | 14 | $226.8K |
| Q2 2023 | 14 | $321.5K |
| Q1 2023 | 11 | $186.0K |
| Q4 2022 | 9 | $110.9K |
| Q3 2022 | 22 | $671.0K |
| Q2 2022 | 27 | $859.0K |
| Q1 2022 | 28 | $1.45M |
| Q4 2021 | 28 | $2.63M |
| Q3 2021 | 27 | $6.84M |
| Q2 2021 | 34 | $10.7M |
| Q1 2021 | 34 | $22.8M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Decoy Therapeutics Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 38,154 | $58.4K | 0.00% | −1,315,219−97.2% | Reduced |
| Renaissance Technologies LLC | 16,342 | $25.0K | 0.00% | −617,919−97.4% | Reduced |
| Geode Capital Management, LLC | 16,523 | $25.0K | 0.00% | −396,612−96.0% | Reduced |
| Advisor Group Holdings, Inc. | 1,387 | $2.00K | 0.00% | −33,313−96.0% | Reduced |
| UBS Group AG | 239 | $366 | 0.00% | −40,609−99.4% | Reduced |
| Morgan Stanley | 63 | $97 | 0.00% | −1,439−95.8% | Reduced |
| BlackRock Inc. | 47 | $72 | 0.00% | −1,150−96.1% | Reduced |
| Wells Fargo & Company | 15 | $23 | 0.00% | −335−95.7% | Reduced |
| Tower Research Capital LLC (TRC) | 533 | $0 | 0.00% | −23,556−97.8% | Reduced |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −310,000−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −142,552−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −115,683−100.0% | Sold out |
| X-Square Capital, LLC | 0 | $0 | 0.00% | −89,000−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −65,022−100.0% | Sold out |
| Horizon Kinetics Asset Management LLC | 0 | $0 | 0.00% | −60,000−100.0% | Sold out |
| Wetherby Asset Management Inc | 0 | $0 | 0.00% | −39,746−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −35,265−100.0% | Sold out |
| ERn Financial, LLC | 0 | $0 | 0.00% | −32,050−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −21,289−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −12,369−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −10,023−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,187−100.0% | Sold out |